HIV

Researchers evaluate potential reasons why HIV some drug combinations are more effective in certain patients.

Current guidelines for treating children with HIV recommend regular medical visits for the first 2 years after care initiation.

Two-drug combination of injectable, long-acting cabotegravir plus rilpivirine monthly or bi-monthly showed comparable efficacy to a daily 3-drug oral therapy at maintaining HIV-1 viral suppression.

The National HIV Surveillance System tracks retention in care for adults diagnosed with HIV, but does not include children in its assessment.

A synthetic particle awakens dormant HIV cells then knocks them out.

A biochip may be able to detect HIV in a drop of blood and display the results within 10 seconds.

Janssen is seeking FDA approval for its once-daily darunavir-based regimen for HIV.

Pharmacists who are unfamiliar with either the principles of infectious disease or HIV may miss errors.

A fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) was non-inferior to boosted protease inhibitor (bPI)-based regimens in virologically suppressed adults with HIV, according to a recently-published phase 3 study.

Achieving National HIV/AIDs target goal could prevent an estimated 200,000 deaths over 20 years, according to a study recently published in the Journal of Infectious Diseases.

The investigational regimen may be appropriate for a broad range of HIV-positive patients.

Reducing the cost of antiretroviral therapy could produce even more savings in the treatment of HIV.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

Surging rates of chlamydia, gonorrhea, and syphilis have affected new populations nationwide.

The 3-in-1 antibody protected laboratory monkeys from SHIV.

Promotion of healthy lifestyle changes are crucial among HIV-positive patients cured of hepatitis C.

Coffee drinking can cut down risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) by half, according to a 5-year study published in the Journal of Hepatology.

Janssen submits new drug application for darunavir-based, once-daily, single-tablet regimen for the treatment of HIV in adults and adolescents who are 12 years of age or older.

As HIV becomes a disease of older Americans, health care professionals need to monitor the age-associated comorbidities among this population.

South African child with HIV reaches 8-plus year survival after only 40 weeks of antiretroviral therapy in infancy.

As HIV becomes a disease of older Americans, it is time for all health care professionals to recognize the age-associated comorbidities unique to this population.

Top news of the day from across the health care landscape.

New PEPFAR strategy supports HIV/AIDS prevention efforts in more than 50 countries.

Traditionally contraindicated in individuals with HIV, thalidomide has utility in aphthous ulcers, gastrointestinal lesions, Kaposi sarcoma, and other HIV-associated developments.

In recent years, thalidomide and similar molecular entities have reentered the clinical milieu and have been approved for several indications.

In Lesotho, more than 67% of all HIV-positive adults ages 15-59 have been able to achieve viral load suppression.

The FDA approval of this 5-nitroimidazole antimicrobial agent was supported by 2 studies of women with BV and an open label safety study, which found efficacy for single-dose secnidazole 2 g.